New combo aims to tame breast cancer with fewer side effects
NCT ID NCT03264547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested whether replacing standard taxane chemotherapy (paclitaxel or docetaxel) with eribulin, when combined with pertuzumab and trastuzumab, could control advanced HER2-positive breast cancer just as well while causing less nerve damage. The study enrolled 446 women who had not received prior chemotherapy for advanced disease. Researchers measured progression-free survival and patient-reported numbness and tingling to compare the two approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eribulin (Halaven), pertuzumab (Perjeta), trastuzumab (Herceptin)
What this could lead to
If successful, this could offer a new chemotherapy option for advanced HER2+ breast cancer that may cause less nerve damage and improve quality of life.
What could go wrong
This is a completed Phase 3 trial, but results may not show a meaningful benefit over standard taxane therapy, and eribulin has its own side effects like fatigue and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan